4 completed, 3 recruiting, 1 active not recruiting, 1 unknown. 9 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 9 | Completed 4, Recruiting 3, Active not recruiting 1, Unknown 1 |
| Phase 2 | 3 | Recruiting 2, Unknown 1 |
Follow envafolimab: new trials by email Literature Review of envafolimab trials Research Report on envafolimab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase I Study to Investigate the Safety and Tolerability of KGX101 Monotherapy and Combination Therapy With Envafolimab in Advanced or Metastatic Solid Tumor Patients KGX101 injection, Envafolimab - Advanced or Metastatic Solid Tumors | Phase 1 | Recruiting | Kangabio AUSTRALIA LTD PTY | 57 | 2024-11-27 | 2026-04-24 |
| RC48 Monotherapy or Combination With Envafolimab for CDK12 Alterations mCRPC With Standard Treatment Failure RC48, Envafolimab - Prostate Cancer, CDK12 Gene Mutation | Phase 1 / Phase 2 | Recruiting | Tianjin Medical University Second Hospital | 72 | 2024-09-24 | 2024-10-29 |
| This is an Open Label, Two-part, Multicenter, Phase I Trial to Investigate the Safety, Tolerability, and PK of KGX101 Monotherapy and Combination Therapy With Envafolimab in Patients With Advanced or Metastatic Solid Tumors. KGX101- Cohort -1, KGX101- Cohort 1, KGX101- Cohort 2 - Advanced or Metastatic Solid Tumors | Phase 1 | Active not recruiting | Kangabio AUSTRALIA LTD PTY | 54 | 2023-12-13 | 2026-04-29 |
| Phase I Trial of Envafolimab for Healthy Male Subjects Envafolimab with new manufacturing process, Envafolimab with old manufacturing process - Healthy Male | Phase 1 | Completed | 3D Medicines (Sichuan) Co., Ltd. | 160 | 2023-05-29 | 2024-08-14 |
| YH001 Plus Envafolimab With or Without Doxorubicin in Patients With Advanced or Metastatic Sarcoma YH001, Envafolimab, Doxorubicin - Advanced Sarcoma, Metastatic Sarcoma | Phase 1 / Phase 2 | Unknown | Tracon Pharmaceuticals Inc. | 15 | 2022-11-14 | 2023-09-21 |
| Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors Lenvatinib + Envafolimab, Sunitinib - Solid Tumors, Non-small Cell Lung Cancer | Phase 1 / Phase 2 | Recruiting | 3D Medicines (Sichuan) Co., Ltd. | 170 | 2021-11-15 | 2026-03-25 |
| A Study of PD-L1 Antibody KN035 in Japanese Subjects With Locally Advanced or Metastatic Solid Tumors KN035 - Advanced or Metastatic Solid Tumors | Phase 1 | Completed | 3D Medicines (Sichuan) Co., Ltd. | 35 | 2017-09-15 | 2022-02-08 |
| Phase I Study of KN035 in Chinese Subjects With Advanced Solid Tumors KN035 - Solid Tumors | Phase 1 | Completed | 3D Medicines (Sichuan) Co., Ltd. | 287 | 2017-03-21 | 2022-03-03 |
| Phase 1 Study of Anti-PD-L1 Monoclonal Antibody KN035 to Treat Locally Advanced or Metastatic Solid Tumors KN035 - Solid Tumors | Phase 1 | Completed | 3D Medicines (Sichuan) Co., Ltd. | 28 | 2017-01-13 | 2021-06-02 |
Carcinoma, Hepatocellular (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Renal Cell (1) · Chondrosarcoma (1) · Diabetes Mellitus, Insulin-Dependent, 12 (1) · Prostatic Neoplasms (1) · Sarcoma (1)
3D Medicines (Sichuan) Co., Ltd. (5) · Kangabio AUSTRALIA LTD PTY (2) · Tianjin Medical University Second Hospital (1) · Tracon Pharmaceuticals Inc. (1)
China (5) · United States (2) · Australia (1) · Japan (1)
David Liu, M.D. (1) · James Freddo, MD (1) · Jun Guo (1) · Qing He (1) · Tianshu Liu (1) · Weidong Jiang, Dr (1)